📊 NWBO Key Takeaways
Is Northwest Biotherapeutics Inc. (NWBO) a Good Investment?
Northwest Biotherapeutics faces imminent financial distress with negative stockholders' equity of -$108.6M, liabilities nearly 4x its assets, and a critical current ratio of 0.08x. Severe cash burn of -$30.6M annually combined with declining revenue (-28.5% YoY) and massive operating losses creates an unsustainable financial position with significant bankruptcy risk.
Fundamentals indicate severe financial distress: minimal revenue, massive recurring losses, and extreme negative margins alongside negative equity. Liquidity is critically tight (0.08x current ratio, $4.56M cash vs. -$30M OCF), with high leverage and negative interest coverage, implying acute going‑concern risk absent immediate, substantial financing or a step-change in revenue.
Why Buy Northwest Biotherapeutics Inc. Stock? NWBO Key Strengths
- Retains $4.6M in cash providing short-term operational runway
- Operates in pharmaceutical sector with potential pipeline assets
- Financial data recently updated (September 2025)
- Capex-light model (only ~$0.6M capex) reduces fixed asset needs
- Slight YoY improvement in net loss and EPS trend
- Existing, albeit small, revenue stream
NWBO Stock Risks: Northwest Biotherapeutics Inc. Investment Risks
- Negative stockholders' equity of -$108.6M indicates technical insolvency
- Critical liquidity crisis with current ratio of 0.08x against $125.9M in liabilities
- Severe operating losses of -$46.4M on only $706K revenue with -6573% operating margin
- Unsustainable cash burn of -$30.6M annually leaves only 1-2 months of runway at current rate
- Declining revenue trajectory (-28.5% YoY) suggests deteriorating business viability
- Unable to service $72.2M long-term debt from operations with negative operating cash flow
- Liquidity crisis: current ratio 0.08x and limited cash
- Solvency risk: negative equity and high liabilities/debt with negative interest coverage
- Sustained heavy cash burn and ultra-negative margins requiring dilutive financing or restructuring
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Revenue stabilization or acceleration indicators
- Capital raise, debt restructuring, or merger announcements
- Quarterly operating loss trajectory and cash flow trends
- Cash runway (cash & equivalents vs operating cash flow)
- Current ratio and interest coverage
Northwest Biotherapeutics Inc. (NWBO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NWBO Profit Margin, ROE & Profitability Analysis
NWBO vs Healthcare Sector: How Northwest Biotherapeutics Inc. Compares
How Northwest Biotherapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Northwest Biotherapeutics Inc. Stock Overvalued? NWBO Valuation Analysis 2026
Based on fundamental analysis, Northwest Biotherapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Northwest Biotherapeutics Inc. Balance Sheet: NWBO Debt, Cash & Liquidity
NWBO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Northwest Biotherapeutics Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
NWBO Revenue Growth, EPS Growth & YoY Performance
NWBO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $200.0K | -$19.4M | $-0.02 |
| Q2 2025 | $131.0K | -$15.4M | $-0.01 |
| Q1 2025 | $284.0K | -$18.3M | $-0.01 |
| Q3 2024 | $357.0K | -$19.4M | $-0.02 |
| Q2 2024 | $201.0K | -$14.4M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Northwest Biotherapeutics Inc. Dividends, Buybacks & Capital Allocation
NWBO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Northwest Biotherapeutics Inc. (CIK: 0001072379)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NWBO
What is the AI rating for NWBO?
Northwest Biotherapeutics Inc. (NWBO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NWBO's key strengths?
Claude: Retains $4.6M in cash providing short-term operational runway. Operates in pharmaceutical sector with potential pipeline assets. ChatGPT: Capex-light model (only ~$0.6M capex) reduces fixed asset needs. Slight YoY improvement in net loss and EPS trend.
What are the risks of investing in NWBO?
Claude: Negative stockholders' equity of -$108.6M indicates technical insolvency. Critical liquidity crisis with current ratio of 0.08x against $125.9M in liabilities. ChatGPT: Liquidity crisis: current ratio 0.08x and limited cash. Solvency risk: negative equity and high liabilities/debt with negative interest coverage.
What is NWBO's revenue and growth?
Northwest Biotherapeutics Inc. reported revenue of $706.0K.
Does NWBO pay dividends?
Northwest Biotherapeutics Inc. does not currently pay dividends.
Where can I find NWBO SEC filings?
Official SEC filings for Northwest Biotherapeutics Inc. (CIK: 0001072379) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NWBO's EPS?
Northwest Biotherapeutics Inc. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NWBO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Northwest Biotherapeutics Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NWBO stock overvalued or undervalued?
Valuation metrics for NWBO: ROE of N/A (sector avg: 15%), net margin of -8,718.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NWBO stock in 2026?
Our dual AI analysis gives Northwest Biotherapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NWBO's free cash flow?
Northwest Biotherapeutics Inc.'s operating cash flow is $-30.0M, with capital expenditures of $599.0K. FCF margin is -4,334.0%.
How does NWBO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,718.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).